TICKERNERD
Menu
AARDAARDHealthcare · Biotechnology

AARD Stock Forecast: Aardvark Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$6.54
+2.03% on the day

The 12 Wall Street analysts covering Aardvark Therapeutics, Inc. hold a median 12-month price target of $6.5 — -0.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 14 Aug 2026 — in the weakest quartile.

Market cap
$143.1M
Ticker Nerd rank
17 / 100
Median analyst target
$6.50
Analysts covering
12
Total return, dividends reinvested
1W
−17.2%
1M
+4.5%
YTD
−50.2%
1Y
−41.9%
From 52W high
−62.4%
From 52W low
+87.9%
$3
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AARD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aardvark Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Aug 2026
17 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
72
Revisions
60
Accruals
38
Value
33
Issuance
33
Quality
29
Growth
17
Volatility
7
Momentum
5

Size (72): Smaller than most of the companies we track.

Momentum (5): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AARD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AARD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26AARDHigh $45.00Median $6.50Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says12 analysts
6 Buy4 Hold2 Sell
Low $3.00Median $6.50High $45.00

The green dot is the last close — the median target sits −0.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 July 2026HC Wainwright & Co.ReiteratesNeutral$6.00
15 May 2026B. Riley SecuritiesMaintainsBuy—
15 May 2026B. Riley SecuritiesMaintainsBuy$8.00 → $7.00
15 May 2026BTIGDowngradeNeutral—
15 May 2026BTIGDowngradeNeutral—
15 May 2026Morgan StanleyDowngradeUnderweight$7.00 → $3.00
15 May 2026Morgan StanleyDowngradeUnderweight—
24 Mar 2026BTIGReiteratesBuy—
2 Mar 2026BTIGMaintainsBuy—
2 Mar 2026HC Wainwright & Co.DowngradeNeutral—
2 Mar 2026Morgan StanleyDowngradeEqual-Weight—
2 Mar 2026OppenheimerMaintainsOutperform—
2 Mar 2026RBC CapitalDowngradeSector Perform—
2 Mar 2026StifelDowngradeHold—
10 Feb 2026BTIGReiteratesBuy—
9 Feb 2026HC Wainwright & Co.ReiteratesBuy—
23 Dec 2025OppenheimerInitiatesOutperform—
12 Dec 2025William BlairInitiatesOutperform—
14 Nov 2025RBC CapitalMaintainsOutperform—
7 Nov 2025BTIGInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AARD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AARD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Aardvark Therapeutics, Inc. (AARD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.2×

Cheaper than 85% of US stocks

Price / sales
—
Price / book
1.9×

Cheaper than 48% of US stocks

EV / EBITDA
−0.9×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−66.0%

Higher than 18% of US stocks

Return on assets
−40.4%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AARD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AARDAardvark Therapeutics, Inc.$143.1M
17
OTLKOutlook Therapeutics, Inc.$141.4M
3
CUECue Biopharma, Inc.$143.7M
72
TLSATiziana Life Sciences Ltd. (Bermuda)$145.6M
21
UNCYUnicycive Therapeutics, Inc.$147.1M
31
NRXPNRX Pharmaceuticals, Inc.$137.2M
21
LENZLENZ Therapeutics, Inc.$148.0M
24

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aardvark Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AARD news & analysis

Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

GlobeNewsWire · 11 Aug 2026neutral

Aardvark Therapeutics reported its second quarter 2026 financial results and provided business updates. The company is currently assessing unblinded Phase 3 HERO and OLE data for ARD-101 in Prader-Willi syndrome (PWS) in the third quarter of 2026 to determine next steps.

Why it matters — AARD watchers will be following the company's assessment of the Phase 3 HERO and OLE data for lead candidate ARD-101 in PWS, which will inform critical decisions on the program's future.

FAQ

Frequently asked questions about AARD stock

What is the AARD stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Aardvark Therapeutics, Inc. have a median 12-month price target of $6.5, with estimates ranging from $3 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AARD stock a buy right now?

Of the 12 analysts covering Aardvark Therapeutics, Inc., 6 rate it a Buy, 4 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Aardvark Therapeutics, Inc. 17 out of 100 across roughly 4,600 US stocks as at 14 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AARD?

As at 14 Aug 2026, Aardvark Therapeutics, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (72 of 100).

Will AARD stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies -0.6% from the last close, and Ticker Nerd's factor model ranks Aardvark Therapeutics, Inc. 17 out of 100 as at 14 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AARD stock forecast for 2030?

No analyst covering Aardvark Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AARD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $45 over the next 12 months.

How has AARD stock performed over the past year?

Aardvark Therapeutics, Inc. returned -41.9% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aardvark Therapeutics, Inc. do?

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel small-molecule therapies for metabolic and hunger-associated disorders.

What is the latest news on AARD?

The most recent item we track (GlobeNewsWire, 11 Aug 2026): "Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates". Aardvark Therapeutics reported its second quarter 2026 financial results and provided business updates. The company is currently assessing unblinded Phase 3 HERO and OLE data for ARD-101 in Prader-Willi syndrome (PWS) in the third quarter of 2026 to determine next steps.

Company

About Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel small-molecule therapies for metabolic and hunger-associated disorders. The company focuses on activating innate homeostatic pathways, particularly through selective targeting of Bitter Taste Receptors (TAS2Rs) in the gut to modulate appetite and related metabolic processes. Its lead product candidate, ARD-101, is an oral, gut-restricted small-molecule agonist of specific TAS2Rs being evaluated in advanced clinical trials for hyperphagia associated with Prader-Willi Syndrome and other hypothalamic causes of excessive hunger. Aardvark Therapeutics is also developing ARD-201, a small-molecule candidate in early-stage clinical development for obesity. Operating in the healthcare sector within the biotechnology industry, the company aims to address significant unmet medical needs in metabolic disease and weight management. Aardvark Therapeutics was incorporated in 2017 and is headquartered in San Diego, California, serving a global biopharmaceutical market through its research, development, and clinical collaboration activities.

CEO Dr. Tien-Li Lee M.D. · 28 employees · United States · https://aardvarktherapeutics.com